Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma

Scientific publication - Journal Article uoadl:3109547 23 Read counter

Unit:
NKUA research material
Title:
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
Languages of Item:
English
Abstract:
Malignantmesothelioma (MM) is an aggressive tumour with poor prognosis whose early diagnosis is difficult. Mesothelin, megakaryocyte potentiating factor (MPF) and osteopontin have attracted attention as biomarkers. The aim of the present review is to provide an overview regarding these candidate biomarkers for MM, and discuss their potential role in today's clinical practice. Mesothelin and MPF have good specificity but sub-optimal sensitivity for detection of MM, being negative both in the sarcomatoid histological sub-type and in almost half of epithelioid mesothelioma, especially in the early stages. Osteopontin is a marker of the duration of asbestos exposure, but lacks specificity for mesothelioma. Several patient characteristics influence the diagnostic accuracy of biomarkers and make the establishment of the 'optimal' diagnostic threshold difficult. Mesothelin and MPF have proved useful in assessing response to treatment. Combining different markers together may lead to an improvement in diagnostic accuracy, but there is still need for research in this area. Extensive validation and further research is required to improve the use of serum markers in mesothelioma management. In the near future, their application in clinical practice is probably in monitoring response to therapy, rather than in guiding diagnostic decisions and risk assessment of asbestos-exposed populations.
Publication year:
2013
Authors:
Pantazopoulos, I.
Boura, P.
Xanthos, T.
Syrigos, K.
Journal:
The European respiratory journal
Volume:
41
Number:
3
Pages:
706-715
Keywords:
antineoplastic agent; asbestos; biological marker; CA 125 antigen; cytokeratin 19; cytokine; hyaluronic acid; megakaryocyte potentiating factor; mesothelin; osteopontin; unclassified drug, area under the curve; blood level; cancer prognosis; cancer screening; clinical practice; cytology; diagnostic accuracy; diagnostic test accuracy study; diagnostic value; ELISA kit; enzyme linked immunosorbent assay; histopathology; human; intermethod comparison; kidney dysfunction; malignant mesothelioma; medical decision making; medical research; occupational exposure; overall survival; patient monitoring; pleura fluid; predictive value; priority journal; protein family; receiver operating characteristic; review; risk assessment; sensitivity and specificity; systematic review; treatment outcome; treatment response; tumor volume; urine level, Asbestos; Early Detection of Cancer; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lung Neoplasms; Mesothelioma; Osteopontin; Pleura; Pleural Neoplasms; Prognosis; Risk Assessment; Tumor Markers, Biological
Official URL (Publisher):
DOI:
10.1183/09031936.00226111
The digital material of the item is not available.